TYBR Health raises $30M series a
Announced 28 July 2026
◆ The Round
TYBR Health raised $30M in series a funding, announced on 28 July 2026, led by Vensana Capital, Mutual Capital Partners, with participation from Neovate Capital Partners. The round is tracked live by Fusion42 as part of the Raise fund database and the Scout startup database.
◆ About TYBR Health
Houston-based healthtech startup that develops the B3 GEL System, a flowable extracellular matrix hydrogel designed to protect tendons and soft tissue from scarring during orthopedic surgery. TYBR Health is based in United States and currently at series a stage, operating in Medtech.
◆ Investors
LeadVensana Capital, Mutual Capital Partners
ParticipationNeovate Capital Partners
◆ Market context
This funding event is a citable node in Fusion42's market graph: it links TYBR Health's Scout profile to the funds behind the round and to related Wire analysis, and is refreshed from public announcements as the round is confirmed or extended. It is the same live market data Arthur reasons over when benchmarking a founder's own raise against what is closing in the market right now.
◆ Explore the market
◆ FAQ
How much did TYBR Health raise?
TYBR Health raised $30M in its series-a round, announced 2026-07-28.
Who invested in TYBR Health's series-a round?
The round was led by Vensana Capital and Mutual Capital Partners, with participation from Neovate Capital Partners.
What does TYBR Health do?
Houston-based healthtech startup that develops the B3 GEL System, a flowable extracellular matrix hydrogel designed to protect tendons and soft tissue from scarring during orthopedic surgery.
Verified 28 July 2026 · Sources: public filings